Clostridium difficile infection (CDI) is diagnosed with the help of
conventional laboratory testing methods, however, rapid point-of-care
diagnostic tests are also available, which can save time and costs
significantly. Diagnostic assays used for detection of CDI include
enzyme immunoassays (EIAs) for toxins A/B. However, these are no
longer considered stand-alone primary tests due to poor sensitivity.
Other tests include glutamate dehydrogenase enzyme immunoassay and
molecular assay based on polymerase chain reaction. Isothermal
amplification technology has also been approved by the U.S. Food &
Drug Administration for diagnosis of CDI. Manufacturers such as
Cepheid, BD Diagnostics, DiaSorin, Inc., Abbott Laboratories, Thermo
Fisher Diagnostics, and Luminex Corporation offer advanced diagnostic
tests for clostridium difficile infection. For instance, Cepheid
GeneXpert test, Nanosphere Verigene SP by Luminex Corporation offer
sensitivity and timely results for clostridium difficile infection.
Request
For Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1499
Market Dynamics
Factors such as rising prevalence of clostridium difficile infection,
availability of precise and advanced diagnostic techniques such as
real time-polymerase chain reaction (RT-PCR), and presence of generic
versions of standard antibiotics such as metronidazole is expected to
boost growth of the clostridium difficile diagnostics and treatment
market over the forecast period. Furthermore, various organizations
and manufacturers are working towards increasing awareness about
clostridium difficile infection and its severity. For instance, in
March 2018, C Diff Foundation awarded its “Making a Difference”
award to CutisPharma, Inc.—a pharmaceutical company, for
contribution of the company towards increasing awareness and
expanding treatment options.
Rising prevalence of clostridium difficile infection is expected
to boost growth of the market over the forecast period
Incidence of clostridium difficile infection has been witnessing an
increase in the recent past, due to clostridium difficile infection
recurrence and antibiotic resistance. According to Centers for
Disease Control and Prevention (CDC), 2015, around half a million
people in the U.S. suffer from clostridium difficile infection in a
year. Moreover, according to National Center for Biotechnology
Information (NCBI), an estimated 37,900 patients were suffering from
clostridium difficile infection in Canada in 2012. A review and
meta-analysis of studies published in National Center for
Biotechnology Information (NCBI), 2016, conducted in China between
2010 and 2016 showed significant incidence of clostridium difficile
infection in China. Furthermore, according to Canadian Antimicrobial
Resistance Surveillance System 2017 Report, clostridium difficile
infection may be a consequence of commonly prescribed antibiotics for
unrelated infections. According to Organization for Economic
Co-operation and Development (OECD), 2015, antibiotic resistant
bacteria are highly prevalent in G7 countries. This high presence of
antibiotic resistant bacteria may lead to increasing incidence of the
infection, which in turn is expected to aid in growth of the global
clostridium difficile diagnostics and treatment market.
Top Key Players
Some major players operating in the clostridium difficile diagnostics
and treatment market include Roche AG, Thermo Fisher Scientific Inc.,
Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc.,
Trinity Biotech, Summit Therapeutics, Baxter International Inc.,
Sanofi S.A., Novartis AG, and AstraZeneca Plc.
Detailed Segmentation:
Global Clostridium Difficile Diagnostics and Treatment Market, By
Product Type:
By Drug
• Metronidazole
• Vancomycin
• Fidaxomicin
• Bezlotoxumab
By Diagnostic Test
• Enzyme Immunoassays
• Real-Time Polymerase Chain Reaction (RT-PCR)
• Nucleic Amplification Tests (NAAT)
• Others
Global Clostridium Difficile Diagnostics and Treatment Market, By
Distribution Channel:
• Hospitals & Clinics
• Diagnostic Laboratories
• Pharmacies
Browse
Full Report @
https://www.coherentmarketinsights.com/market-insight/clostridium-difficile-diagnostics-and-treatment-market-1499
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment